2015

Aveo announces executive transition, corporate restructuring

Thursday, January 8, 2015

Aveo Oncology, based in Cambridge, Mass., has appointed Michael P. Bailey as the company’s president, CEO and director, effective immediately. Aveo also said it will eliminate the company’s internal research function, as well as certain corporate support positions, to align corporate resources with the company’s future strategic plans, focusing on advancement of its pipeline in the clinical setting.

[Read More]

Adaptive Biotechnologies acquires Sequenta

Thursday, January 8, 2015

Adaptive Biotechnologies, a platform-based, diagnostic-driven company headquartered in Seattle, Wash., has acquired Sequenta, a California company focused on the development of clinical diagnostics using immunosequencing. The acquisition is expected to expedite and expand the use of novel immunosequencing products for researchers and clinicians to diagnose, treat and monitor patients with cancer, autoimmune disorders and infectious diseases.

[Read More]

Heptares expands board of directors

Thursday, January 8, 2015

Heptares Therapeutics, a clinical-stage GPCR structure-guided drug discovery and development company, has appointed Atul Pande and Roberto Solari to its board of directors. Pande and Solari bring significant industry experience in the discovery and validation of drug targets and the subsequent development of novel medicines.

[Read More]

Radiant Sage releases RadClinica version 3.0

Wednesday, January 7, 2015

Radiant Sage, a provider of on-demand clinical trial imaging infrastructure solutions headquartered in Belmont, Mass., has released its Clinical Trial Management System (CTMS), RadClinica version 3.0. This single, centralized system adds to the Corelab-In-A-Box platform by providing a set of features to manage the execution of multiple imaging studies with real-time access in a cloud-based platform.

[Read More]

Isis Pharmaceuticals, Janssen collaborate

Wednesday, January 7, 2015

Isis Pharmaceuticals, based in Carlsbad, Calif., has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract. The collaboration brings together Isis’ RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders in the GI tract.

[Read More]

Certara’s Synchrogenix acquires ClinGenuity

Wednesday, January 7, 2015

Synchrogenix, the regulatory and medical consultancy of Certara, a Princeton, N.J.-based global biosimulation technology-enabled drug development and drug safety consulting company, has acquired ClinGenuity, a Cincinnati-based artificial intelligence-assisted medical writing service. Their combined team now will include more than 200 regulatory and medical writers with experience in document development for the FDAEMA and other global regulatory organizations.

[Read More]

Sciformix expands, adds new office in the U.K.

Wednesday, January 7, 2015

Sciformix, a scientific process organization (SPO) located in Westborough, Mass., has opened a new office in Manchester, U.K., expanding its global presence and footprint to include the European region. Sciformix supports life science organizations with high quality services in safety and risk management, regulatory affairs and operations and clinical research and post-approval support.

[Read More]